Oakes Gregory — SEC Form 4 filings
SEC reporting owner CIK 1809796. 2 Form 4 filings on record with FilingPulse; latest filed 2024-05-23.
Transaction summary — filings shown
Covers all 2 filings on record, filed 2024-03-04 to 2024-05-23. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 4.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Landos Biopharma, Inc. (LABP) | Chief Executive Officer, Director | 2 | — | — | 4 |
Form 4 filings — Oakes Gregory
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2024-05-23 | 4 | Landos Biopharma, Inc. (LABP) | Disposition to issuer (D): 54,454 (derivative) · Disposition to issuer (D): 47,529 (derivative) · Disposition to issuer (D): 167,724 (derivative) | EDGAR |
| 2024-03-04 | 4 | Landos Biopharma, Inc. (LABP) | Grant/award (A): 54,454 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1809796 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →